Everything below concerns mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Owing to its distance from open sea and its position on the southeastern portion of the European continent, Romania has a climate that is continental, with four distinct seasons. The average annual temperature is 11 °C (52 °F) in the south and 8 °C (46 °F) in the north. In summer, average maximum temperatures in Bucharest rise to 28 °C (82 °F), and temperatures over 35 °C (95 °F) are fairly common in the lower-lying areas of the country. In winter, the average maximum temperature is below 2 °C (36 °F). Precipitation is average, with over 750 mm (30 in) per year only on the highest western mountains, while around Bucharest it drops to approximately 570 mm (22 in). There are some regional differences: in western sections, such as Banat, the climate is milder and has some Mediterranean influences; the eastern part of the country has a more pronounced continental climate. In Dobruja, the Black Sea also exerts an influence over the region's climate.
The University Grants Committee funds eight public universities in Hong Kong. The Hong Kong Academy for Performing Arts also receives funding from the government. There are four self-financing universities, namely Hong Kong Metropolitan University, Hong Kong Shue Yan University, Hang Seng University of Hong Kong, and Saint Francis University.
=== Visiting professorships === He has had visiting professorships at UC Berkeley; University of Chieti, Italy; University of Perugia, Italy; the Scripps Research Institute, La Jolla, California; and the Collège de France, Paris
=== Synthesis === The cyclic dipeptide Epelsiban is formed by cyclizing the corresponding linear dipeptide. In the highly stereoselective synthesis of Epelsiban 11, the linear peptide 8 is formed by the four-component Ugi reaction of the carboxybenzyl (Cbz) protected R-indanylglycine 4, D-alloisoleucine methyl ester hydrochloride 5, 2,6-dimethylpyridine-3-carboxaldehyde 6 and 2-benzyloxyphenylisonitrile 7. Hydrogenation to remove the Cbz and benzyl protecting groups, enabled cyclization of the linear peptide 8 to occur to give the phenolic cyclic dipeptide 9. Hydrolysis of the phenolic amide, by reaction with carbonyl diimidazole (CDI), followed by the addition of aqueous hydrochloric acid gave the acid 10 which was converted to the amide Epelsiban 11 by activating the acid with the peptide coupling reagent CDI, followed by the addition of morpholine. In this short lab-scale synthesis although the linear peptide 8 and the cyclic dipeptide 9 are a mixture of diastereoisomers (7RS) at the exocyclic amide, the hydrochloric acid hydrolysis of the activated phenolic amide caused epimerisation at the exocyclic position and yielded the acid 10 with the required (7R)-stereochemistry as the major product.
=== Removal of additives === In 2011, food blogger and activist Vani Hari noted that Chick-fil-A sandwiches contained nearly 100 ingredients, including peanut oil preserved with tert-butylhydroquinone (TBHQ), made from butane. In October 2012, Chick-fil-A invited Hari to meet with company executives at its headquarters. In December 2013, Chick-fil-A said that it was removing high-fructose corn syrup and artificial dyes, and was testing a new peanut oil. Like other companies, Chick-fil-A does not publicly announce such changes unless already in the news, because it focuses on these ingredients.
Sources: en.wikipedia.org
One should expect that, within a few thousand years of its entering the stage of industrial development, any intelligent species should be found occupying an artificial biosphere which surrounds its parent star. Dyson conceived that such structures would be clouds of asteroid-sized space habitats, though science fiction writers have preferred a solid structure: either way, such an artifact is often called a Dyson sphere, although Dyson used the term "shell". Dyson said that he used the term "artificial biosphere" in the article to mean a habitat, not a shape. The general concept of such an energy-transferring shell had been created decades earlier by science fiction writer Olaf Stapledon in his 1937 novel Star Maker, a source which Dyson credited publicly. Freeman Dyson was interviewed by Robert Wright in 2003 and the Dyson Sphere topic was broached. In response he stated that the paper he wrote on this concept was intended to be a joke and had nothing to do with work. He added that it amused him that he had become famous only for the things he didn't think were serious.
===== MeSH D08.811.682.662 – oxidoreductases acting on ch-nh group donors ===== MeSH D08.811.682.662.162 – dihydropteridine reductase MeSH D08.811.682.662.171 – FMN reductase MeSH D08.811.682.662.217 – methylenetetrahydrofolate dehydrogenase (nad+) MeSH D08.811.682.662.253 – methylenetetrahydrofolate dehydrogenase (nadp) MeSH D08.811.682.662.290 – methylenetetrahydrofolate reductase (nadph2) MeSH D08.811.682.662.582 – oxidoreductases, n-demethylating MeSH D08.811.682.662.582.276 – aminopyrine n-demethylase MeSH D08.811.682.662.582.338 – cytochrome p-450 cyp2e1 MeSH D08.811.682.662.582.353 – cytochrome p-450 cyp3a MeSH D08.811.682.662.582.361 – dihydropteridine reductase MeSH D08.811.682.662.582.369 – dimethylglycine dehydrogenase MeSH D08.811.682.662.582.400 – ethylmorphine-n-demethylase MeSH D08.811.682.662.582.550 – sarcosine dehydrogenase MeSH D08.811.682.662.582.700 – sarcosine oxidase MeSH D08.811.682.662.640 – proline oxidase MeSH D08.811.682.662.680 – pyridoxamine-phosphate oxidase MeSH D08.811.682.662.693 – 1-pyrroline-5-carboxylate dehydrogenase MeSH D08.811.682.662.695 – pyrroline carboxylate reductases MeSH D08.811.682.662.750 – saccharopine dehydrogenases MeSH D08.811.682.662.825 – tetrahydrofolate dehydrogenase
== Indian Biological Data Centre == Department of Biotechnology announces the launch of first Indian Biological Data Centre (IBDC) at Regional Centre for Biotechnology, Faridabad. A national facility to store, manage, archive and distribute all kind of biological data.
=== Dinoflagellates in the Adriatic Sea === The marine dinoflagellates: Prorocentrum micans, Lingulodinium polyedra, Gymnodinium sp., and Alexandrium tamarense, were collected from the Adriatic Sea during red-tide blooms and their 4-methyl sterol content was investigated. Dinosterol is the major component in P. micans, L. polyedra, and Gymnodinium strains, suggesting that dinosterol is a good biomarker because of its high abundance in most of the analyzed dinoflagellates.
Co-Founder and Co-Chair, Chinese Welfare Trust and Trustee, Islington Chinese Association. For services to the Chinese Community in London. Philip Richard Chandler. For services to the community in Herefordshire. Patrick Chapman. For services to the Creative Industries and to Higher Education. Robert Christie. Head Coach, Scotland Paralympic Lawn Bowls Team. For services to Lawn Bowls. Michael Cladingbowl. For services to Education. David McCrorie Shearer Clark. School Support Officer, Aberdeenshire Council. For services to Education. Emilia Isobel Euphemia Rose Clarke. Co-Founder and Trustee, SameYou. For services to People with Brain Injuries. Jennifer Susan Dodd Clarke. Co-Founder and Chief Executive Officer, SameYou. For services to People with Brain Injuries. Gillian Petrina Clayton. Intelligence Led Programme Manager, Environment Agency. For services to Environmental Crime, Enforcement and Intelligence. William Cleere. Committee Member, Berkshire and Buckinghamshire Referees Association. For services to the community in Buckinghamshire. David Clifford. Fundraiser, Macmillan Cancer Support. For services to Charitable Fundraising in Clackmannanshire. David Lampton Grey Cochrane. Head of Forensic Social Work, Forensic Mental Health and High Secure Care, West London NHS Trust. For services to Health and Social Care. Joan Lorna Jeannette Cocking. Chair of Governors, Kent College Canterbury. For services to Education. Justin Anthony Cohen. News Editor, Jewish News. For services to Holocaust Remembrance and to the Jewish Community. Robert George Coles.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.